Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping–Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report

Documenti analoghi

• Hotspot Exon 15 Mutations in BRAF Are Uncommon in Feline Tumours
  di: Kei Kuroki, et al.
  Pubblicazione: (2024)
• Dual Immunotherapy for Pericardial Mesothelioma That Developed After a Decade‐Long Idiopathic Pericarditis: A Case Report
  di: Beatriz Grau Mirete, et al.
  Pubblicazione: (2025)
• Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination
  di: Yoshiki Kato, et al.
  Pubblicazione: (2025)
• Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation
  di: Xiaohui Du, et al.
  Pubblicazione: (2025)
• Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression
  di: Elisa Carouge, et al.
  Pubblicazione: (2024)